Cramer Joyce A, Claude Simeoni Marie, Auquier Pascal, Robitail Stéphane, Brasseur Pascale, Beresniak Ariel
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
J Adolesc. 2005 Aug;28(4):595-600. doi: 10.1016/j.adolescence.2004.11.003.
This study assessed the psychometric properties of a recently developed health-related quality of life (HRQOL) instrument (Vécu et Santé Perçue de l'Adolescent -Malade, VSP-AM) in 172 adolescents receiving growth hormone. The VSP-AM was cross-culturally adapted into English and tested for internal consistency (alpha=0.78-0.89 subscales, 0.74 Summary Score), construct and criterion validity, and responsiveness. Correlations with other scales demonstrated convergent validity. Adolescents who reported HRQOL as high or low had significantly different scores (all p<0.001). Adolescents receiving growth hormone therapy differed significantly from adolescents with medical, surgical or psychiatric disorders. The VSP-AM shows reliability and validity for HRQOL measurement in adolescents with growth disorders.
本研究评估了一种最近开发的健康相关生活质量（HRQOL）工具（青少年患者的生活与健康感知，VSP-AM）在172名接受生长激素治疗的青少年中的心理测量特性。VSP-AM经过跨文化改编成英文，并测试了内部一致性（各分量表α=0.78-0.89，总得分α=0.74）、结构效度、效标效度和反应度。与其他量表的相关性证明了收敛效度。报告HRQOL高或低的青少年得分有显著差异（所有p<0.001）。接受生长激素治疗的青少年与患有内科、外科或精神疾病的青少年有显著差异。VSP-AM在评估患有生长障碍的青少年的HRQOL方面显示出可靠性和有效性。
